[go: up one dir, main page]

AR132852A1 - Combiterapia para tratar el cáncer - Google Patents

Combiterapia para tratar el cáncer

Info

Publication number
AR132852A1
AR132852A1 ARP240101413A ARP240101413A AR132852A1 AR 132852 A1 AR132852 A1 AR 132852A1 AR P240101413 A ARP240101413 A AR P240101413A AR P240101413 A ARP240101413 A AR P240101413A AR 132852 A1 AR132852 A1 AR 132852A1
Authority
AR
Argentina
Prior art keywords
combitherapy
treat cancer
subject
administering
compound
Prior art date
Application number
ARP240101413A
Other languages
English (en)
Inventor
Alexis Borisy
Nicholas Lydon
George Demetri
Robert Forrester
Ben Auspitz
Vivek Kadambi
Jessica Christo
Original Assignee
Idrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idrx Inc filed Critical Idrx Inc
Publication of AR132852A1 publication Critical patent/AR132852A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un método para tratar un cáncer en un sujeto que lo necesite, que comprende administrarle al sujeto: M4205 o una sal farmacéuticamente aceptable de este, y un compuesto de fórmula (1).
ARP240101413A 2023-06-02 2024-06-03 Combiterapia para tratar el cáncer AR132852A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363506045P 2023-06-02 2023-06-02

Publications (1)

Publication Number Publication Date
AR132852A1 true AR132852A1 (es) 2025-08-06

Family

ID=91853259

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101413A AR132852A1 (es) 2023-06-02 2024-06-03 Combiterapia para tratar el cáncer

Country Status (4)

Country Link
CN (1) CN121194786A (es)
AR (1) AR132852A1 (es)
TW (1) TW202504584A (es)
WO (1) WO2024249855A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2922841B8 (en) * 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
SG11201602937UA (en) * 2013-10-17 2016-05-30 Blueprint Medicines Corp Compositions useful for treating disorders related to kit
WO2021204626A1 (en) * 2020-04-06 2021-10-14 Almirall, S.A. Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors
AU2023255386A1 (en) * 2022-04-19 2024-10-31 Blueprint Medicines Corporation Kit inhibitors

Also Published As

Publication number Publication date
CN121194786A (zh) 2025-12-23
TW202504584A (zh) 2025-02-01
WO2024249855A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
MX2022012714A (es) Inhibidores de la replicacion de norovirus y coronavirus.
CL2022002592A1 (es) Uso de agentes para el tratamiento de condiciones respiratorias
AR119158A1 (es) Tratamientos de angioedema hereditario
PE20242201A1 (es) Tratamiento de neurofibromas cutaneos con mirdametinib
CL2025000970A1 (es) Compuesto inhibidor de parg
CL2023000857A1 (es) Inhibidores line-1 para tratar la enfermedad
AR119430A1 (es) Métodos para tratar o prevenir la atrofia muscular espinal
MX2025003008A (es) Regimen de dosificacion para el tratamiento de la pku con un inhibidor de la funcion de slc6a19 como piperidina
MX2019001412A (es) Compuestos de 9-aminometil minociclina y usos de los mismos.
AR128711A1 (es) Métodos para tratar carcinoma microcítico de pulmón
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
MX2022011240A (es) Azálidos de urea inmunomoduladores.
CO2025016753A2 (es) Inhibidores de gsk3α y métodos de uso de estos
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
CL2025001119A1 (es) Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina
AR132852A1 (es) Combiterapia para tratar el cáncer
AR131842A1 (es) Métodos para tratar gliomas
AR129959A1 (es) Método para tratar enfermedades o trastornos orgánicos con inhibidores de ask1
UY39593A (es) Tratamiento para tumores sólidos malignos
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
MX2023010849A (es) Métodos de tratamiento.
AR118933A1 (es) Dosificación del inhibidor de kras para el tratamiento de cánceres
CL2025000332A1 (es) Tratamiento de la urticaria con inhibidores de jak.
AR133820A1 (es) Combinación de un inhibidor de wee1 y un inhibidor de pkmyt1
AR122400A1 (es) Uso de agentes para el tratamiento de afecciones respiratorias